MacroGenics (NASDAQ:MGNX) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of MacroGenics (NASDAQ:MGNX) from a sell rating to a hold rating in a research note published on Tuesday, February 13th.

According to Zacks, “MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. “

MGNX has been the topic of a number of other reports. BidaskClub lowered shares of MacroGenics from a sell rating to a strong sell rating in a report on Thursday, December 14th. Cowen reissued a buy rating on shares of MacroGenics in a report on Wednesday, January 24th. SunTrust Banks restated a buy rating and set a $31.00 target price on shares of MacroGenics in a research report on Tuesday, January 23rd. ValuEngine downgraded shares of MacroGenics from a sell rating to a strong sell rating in a research report on Tuesday, November 14th. Finally, Raymond James Financial reiterated a buy rating on shares of MacroGenics in a research report on Monday, December 11th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $30.60.

MacroGenics (NASDAQ MGNX) opened at $23.46 on Tuesday. MacroGenics has a 1-year low of $14.36 and a 1-year high of $24.26.

In other news, SVP Jon Marc Wigginton sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 17th. The shares were sold at an average price of $20.00, for a total value of $100,000.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Eric Blasius Risser sold 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 24th. The stock was sold at an average price of $22.50, for a total transaction of $67,500.00. Following the completion of the transaction, the senior vice president now owns 12,100 shares in the company, valued at $272,250. The disclosure for this sale can be found here. Corporate insiders own 8.30% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Legal & General Group Plc raised its holdings in shares of MacroGenics by 4.3% in the 2nd quarter. Legal & General Group Plc now owns 7,925 shares of the biopharmaceutical company’s stock valued at $138,000 after purchasing an additional 328 shares in the last quarter. Parametric Portfolio Associates LLC purchased a new position in shares of MacroGenics in the 2nd quarter valued at $203,000. Teacher Retirement System of Texas purchased a new position in shares of MacroGenics in the 4th quarter valued at $225,000. Virtu KCG Holdings LLC purchased a new position in MacroGenics during the 2nd quarter worth $232,000. Finally, MetLife Investment Advisors LLC purchased a new position in MacroGenics during the 4th quarter worth $281,000. Institutional investors and hedge funds own 85.30% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://stocknewstimes.com/2018/02/24/macrogenics-mgnx-rating-increased-to-hold-at-zacks-investment-research-2.html.

About MacroGenics

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Get a free copy of the Zacks research report on MacroGenics (MGNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply